TO THE EDITOR:

In reply to your questions about the cases which I reported in my previous letter [The Journal 27 (1959) 268], the following further information is offered.

- 1. The BCG vaccination was for the most part oral in all cases, but some were also given each a single small dose subcutaneously.
- 2. The two cases which had only macular reactional lesions were found bacteriologically negative on first examination, as stated, but later they were found positive. The same was true of one of the cases with nodules; the other was positive on the first examination. The patient with arciform lesions remained bacteriologically negative throughout. So, in all but this last case bacilli were found in varying numbers.
- 3. The last case had been lepromatous, being classified at the Baldomero Sommer Sanitarium as  $L_1N_2$ . Incidentally, he was not an "old man," but an old case, for he had been seen first in 1943.

Summaries of these five cases, and one other, follow.

Case J.L., female, aged 38 in 1949, negative for bacilli and the Mitsuda reaction,

typed I. Sulfone treatment 7 years. No lesions in 1956; B- throughout.

BCG, 3 doses (oral, 100 mgm.) in September 1956, a week apart. In October, there was an eruption of macular lesions; B— at first, then B1+. Further sulfone treatment 3½ years; no lesions in 1960. Meanwhile, B—, B+; M—.

Case A.L., female, aged 9 in 1956, B-, M-; typed I to L. Sulfone treatment 3 months. No lesions in September 1956; B- throughout.

BCG, 4 doses (oral, 200 mgm.) in September-October 1956, at weekly intervals. In February 1957, eruption of macules only; B-, B+. Further sulfone treatment 3 years. No lesions in 1960; B-, M2+.

Case A.F., female, aged 45 in 1954; B-, M-; typed La. Sulfones 2 years. No lesions in 1956; B- since then.

BCG, 2 doses (oral, 200 mgm.) January and March 1956. In July 1956, macules and ENL; B-, B1+. Further sulfones 2 years. No lesions in 1958; B-, M1+.

Case C.S., female, aged 29 in 1953; B1+, M-; typed LaNz. Sulfones 1½ years. No lesions (except neural changes) in 1954; B- since late 1953.

BCG, 2 doses (oral, 100 mgm.) December 1953 and May 1954; also, June 1954, 0.02 mgm. subcutaneous. In August 1954, macules and lepromas; B1, B2+. Further sulfones 1 year. Residual lesions in 1955; B-, M-.

Case E.A., male, aged 9 in 1953; B2+, M-; typed La. Sulfones 1½ years. No lesions in 1954; B-.

BCG 2 doses (oral, 100 mgm.) December 1953 and May 1954; also, June 1954, 0.02 mgm. subcutaneous. In July 1954, macules, lepromas and ENL; B-, B1+. Further sulfones 1 year. No lesions in 1955; B-, M-.

Case J.C.C., male, aged 35 in 1943; B1+, M-; typed L<sub>1</sub>N<sub>2</sub>. Treatment with chaulmoogra, irregularly. No lesions (except neural changes) in 1949.

BCG, subcutaneous 0.02 mgm., January 1953; also 3 oral doses (100 mgm.) June, July and August 1953. In October 1953, arciform macules and plexalgia; B—, persistently. In 1955 (2 years without treatment), no cutaneous lesions; B+, M1+.

Dispensario de la Dirección de Lucha
Dermatológica, Buenos Aires, Argentina
Enrique D. L. Jonquieres
Director